JSPR

Jasper TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$0.90

+55.3% vs current

Most likely

Base case

45%

Probability

Target price

$0.45

-22.3% vs current

B-

Bear case

30%

Probability

Target price

$0.20

-65.5% vs current

AI sentiment snapshot

Latest data as of 2026-07-04

AI commentary

Tone is modestly constructive because primary company sources support protocol progress and prior CSU data strength, but this remains a cautious monitoring setup rather than a high-conviction thesis. Coverage is thin, recent trusted-news flow is sparse, no usable social-context packet was provided, and the main debate is still whether Jasper can finance the next study step on acceptable terms.

RankAlpha Sentiment Codex - 2026-07-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystFinancing is still the gating variable for the next CSU study stepHigh impact

Jasper said it is working to secure additional funding to enable commencement of the planned Phase 2b CSU study in 2H26, while cash was $14.1 million at March 31, 2026 and quarterly R&D plus G&A expense totaled $10.9 million [#SEC-8K-2026-05-14].

2026-10-31eventProtocol refiling and dose selection support operational progress in CSUHigh impact

Management said it analyzed BEACON, SPOTLIGHT, and open-label extension data, selected two active dosing regimens for Phase 2b, and refiled the updated protocol with the FDA, which modestly de-risks execution but does not remove the funding dependency [#SEC-8K-2026-05-14].

2026-12-31catalystActual start of the planned Phase 2b/3 CSU study remains the core rerating hookHigh impact

The main upside catalyst is commencement of the planned Phase 2b/3 CSU study in the second half of 2026, but management tied that timeline to capital availability [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-04 • Updated nightlySource: Internal modelMethodology